CHL-5004
Проводит Takeda
Страница компанииKLIO - Non-interventional Multicenter Prospective and Retrospective Study to Describe Treatment Patterns and Disease Control in Patients With Classical Hodgkin's Lymphoma (cHL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) in Routine Clinical Practice in the Russian Federation
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03942263/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 2000 чел. во всех странах исследования.
- Центров в реестре: 50 в 37 городах. Список — ниже на странице.
- Плановая дата окончания (12.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 3 · невключение: 4
Критерии включения
- Male and female participants 18 years or older by the time of enrollment.
- Histologically confirmed diagnosis of cHL or sALCL.
- Newly diagnosed participants, or participants with RR cHL or RR sALCL at the time of enrollment, or participants with RR cHL or RR sALCL within 3 years prior to inclusion in the Study.
Критерии невключения
- Unconfirmed diagnosis of cHL or sALCL.
- Current, previous (within the last 3 years) or planned (for the next 2 years) participation in interventional clinical trials.
- Participation in the non-interventional study CHL-5001 "An international, multi-centre, non-interventional retrospective study to describe treatment pathways, outcomes, and resource use in participants with classical Hodgkin lymphoma (B-HOLISTIC)" (Sponsor is Takeda Pharmaceuticals International AG).
- Participants for whom the minimum study dataset was not available from their hospital medical records.
Источник: ClinicalTrials.gov, NCT03942263 · запись обновлена в реестре 15 июля 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 42
- Description of Treatment Patterns Used for cHL or sALCL — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
- Percentage of Participants Receiving Various Chemotherapy Regimens — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
- Percentage of Participants who Received Chemotherapy Regimens as per National Guidelines — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
- Percentage of Participants who Received Radiotherapy Including Site (Extended/Involved) and Total Dosing — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
- Percentage of Participants who Received Autologous Stem Cell Transplantation (AutoSCT) — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
- Percentage of Participants who Were Eligible for AutoSCT did not Receive it (Including Reasons) — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
- Percentage of Participants who Received Allogeneic Stem Cell Transplantation (AlloSCT) — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
- Distribution of Pre-SCT Therapy Regimens — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
- Distribution of First Line Treatment Patterns According to Prognostic Group — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
- Distribution of Relapse/Refractory (RR) Treatment Patterns — From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years)
Цель исследования
The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.
Где проходит
50 центров в 37 городах- Moscow City Hematology Center on the basis of the State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital named after S.P. Botkin Moscow Department of Health
- The Moscow State Clinical Hospital No. 52 of the Moscow City Department of Healthcare, State Budgetary Institution of Health Care
- ГБУЗ Московской области «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»
- ФГБУ «Главный военный клинический госпиталь имени академика Н.Н. Бурденко» Минобороны России
- ФГБУ «Национальный медико-хирургический Центр имени Н.И. Пирогова» Минздрава России
- ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России
- ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава России
- North-Western State Medical University named after I. I. Mechnikov
- ГБУЗ Ленинградская областная клиническая больница
- ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова» Минздрава России
- ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства»
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03942263 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.